ATE556046T1 - Interleukin-1- und tumornekrosefaktor-a- modulatoren, synthese solcher modulatoren und verfahren unter anwendung solcher modulatoren - Google Patents

Interleukin-1- und tumornekrosefaktor-a- modulatoren, synthese solcher modulatoren und verfahren unter anwendung solcher modulatoren

Info

Publication number
ATE556046T1
ATE556046T1 AT06787310T AT06787310T ATE556046T1 AT E556046 T1 ATE556046 T1 AT E556046T1 AT 06787310 T AT06787310 T AT 06787310T AT 06787310 T AT06787310 T AT 06787310T AT E556046 T1 ATE556046 T1 AT E556046T1
Authority
AT
Austria
Prior art keywords
modulators
interleukin
synthesis
methods
necrosis factor
Prior art date
Application number
AT06787310T
Other languages
English (en)
Inventor
Michael A Palladino
Emmanuel A Theodorakis
Venkat Rami Reddy Macherla
Ta-Hsiang Chao
Young Ger Suh
Original Assignee
Nereus Pharmaceuticals Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nereus Pharmaceuticals Inc, Univ California filed Critical Nereus Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE556046T1 publication Critical patent/ATE556046T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/557—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78—Separation; Purification; Stabilisation; Use of additives
    • C07C45/79—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/86—Ring systems containing bridged rings containing four rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06787310T 2005-07-21 2006-07-14 Interleukin-1- und tumornekrosefaktor-a- modulatoren, synthese solcher modulatoren und verfahren unter anwendung solcher modulatoren ATE556046T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US70193205P 2005-07-21 2005-07-21
US73467905P 2005-11-07 2005-11-07
US73459005P 2005-11-07 2005-11-07
US74954205P 2005-12-12 2005-12-12
US78522306P 2006-03-22 2006-03-22
PCT/US2006/027385 WO2007015757A2 (en) 2005-07-21 2006-07-14 Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators

Publications (1)

Publication Number Publication Date
ATE556046T1 true ATE556046T1 (de) 2012-05-15

Family

ID=37497889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06787310T ATE556046T1 (de) 2005-07-21 2006-07-14 Interleukin-1- und tumornekrosefaktor-a- modulatoren, synthese solcher modulatoren und verfahren unter anwendung solcher modulatoren

Country Status (11)

Country Link
US (3) US7893299B2 (de)
EP (2) EP2311795A3 (de)
JP (1) JP2009505954A (de)
KR (1) KR20080035650A (de)
AR (1) AR057681A1 (de)
AT (1) ATE556046T1 (de)
AU (1) AU2006276274B2 (de)
CA (1) CA2613366A1 (de)
IL (1) IL188353A0 (de)
TW (1) TW200744992A (de)
WO (1) WO2007015757A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2444092T3 (en) 2008-05-28 2015-09-28 Reveragen Biopharma Inc Non-hormonal steroidmodulatorer of NF-? B for the treatment of disease
WO2010108140A1 (en) * 2009-03-20 2010-09-23 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
CN103180288B (zh) * 2010-10-27 2015-03-25 希格马托制药工业公司 具有生物学特性的二萜类衍生物
EP2785351A4 (de) * 2011-11-29 2015-05-27 Reveragen Biopharma Inc Nichthormonale steroide modulatoren von nf-kb zur behandlung von erkrankugen
EP2794630A4 (de) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituierte phosphorthioat-nukleotidanaloga
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
WO2017004205A1 (en) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
US10494397B2 (en) * 2016-07-15 2019-12-03 Pepsico, Inc. Rebaudioside analogs
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
RU2726613C1 (ru) * 2019-12-16 2020-07-15 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) Карбоксамиды изопимаровой кислоты, обладающие анальгетической активностью

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5212708B2 (de) * 1974-05-14 1977-04-08
JPS522910B2 (de) * 1974-05-17 1977-01-25
GB1452053A (en) * 1974-08-28 1976-10-06 Nippon Shinyaku Co Ltd Abietamide derivatives and a method for the preparation thereof
US4874891A (en) 1986-05-01 1989-10-17 Washington University Open "D" ring hormone analogs
US5501959A (en) 1989-01-17 1996-03-26 Alamar Biosciences Laboratory, Inc. Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
WO1991013855A1 (en) 1990-03-06 1991-09-19 Otsuka Pharmaceutical Co., Ltd. Phenanthrene derivative
US5276182A (en) 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers
DE4039602A1 (de) 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5653962A (en) 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
CA2149150C (en) 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
US5654286A (en) 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
PL177323B1 (pl) 1993-10-01 1999-10-29 Syntex Inc Kompozycja farmaceutyczna zawierająca mykofenolan mofetylu lub kwas mykofenolowy i sposób wytwarzania kompozycji farmaceutycznej zawierającej mykofenolan mofetylu lub kwas mykofenolowy
KR0145941B1 (ko) 1994-06-13 1998-08-17 김은영 인터루킨-1과 종양 괴사 인자-알파의 생산 억제에 유용한 아칸토산을 포함하는 약학적 조성물
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
NL1001681C2 (nl) 1995-11-17 1997-05-21 Geesink Bv Voertuig, in het bijzonder een afvalinzamelvoertuig, voorzien van een veiligheidssysteem.
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
ES2211030T3 (es) 1998-01-26 2004-07-01 Sae Han Pharm. Co., Ltd. Derivados diterpenos y agentes analgesicos anti-inflamatorios que comprenden a los mismos.
US6051590A (en) 1999-05-13 2000-04-18 Merck & Co., Inc. Immunosuppressant tricyclic compounds
PT1178952E (pt) 1999-05-14 2007-12-04 Univ California Novos moduladores da interleucina-1 e do factor alfa de necrose tumoral, síntese dos referidos moduladores e métodos de utilização dos referidos moduladores
WO2002079137A1 (en) * 2001-03-28 2002-10-10 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-alpha modulators and their enantiomers, their synthesis and use
DE102004035203A1 (de) * 2004-07-21 2006-02-16 Bayer Healthcare Ag Substituierte Chinolone

Also Published As

Publication number Publication date
US7893299B2 (en) 2011-02-22
WO2007015757A3 (en) 2007-06-21
AU2006276274B2 (en) 2012-03-29
AU2006276274A1 (en) 2007-02-08
US20080064753A1 (en) 2008-03-13
JP2009505954A (ja) 2009-02-12
US20120238634A1 (en) 2012-09-20
IL188353A0 (en) 2008-04-13
AR057681A1 (es) 2007-12-12
EP2311795A2 (de) 2011-04-20
EP1912932B1 (de) 2012-05-02
KR20080035650A (ko) 2008-04-23
US8133915B2 (en) 2012-03-13
US20110160309A1 (en) 2011-06-30
EP2311795A3 (de) 2011-12-28
EP1912932A2 (de) 2008-04-23
WO2007015757A2 (en) 2007-02-08
CA2613366A1 (en) 2007-02-08
TW200744992A (en) 2007-12-16

Similar Documents

Publication Publication Date Title
DK1913001T3 (da) (r)-n-methylnaltrexon, fremgangsmåder til syntese og farmaceutisk anvendelse heraf
PT3661157T (pt) Métodos e aparelhos para integrar meios de comunicação através de uma rede de área alargada
IL188353A0 (en) Interleukin-1 and tumor necrosis factor-a modulators: syntheses of such modulators and methods of using such modulators
DK1830956T3 (da) Fremgangsmåde til forberedelse af katalytiske materialer
DK1748077T3 (da) Fremgangsmåde til fremstilling af protein
NO20082160L (no) Nye vanilloidreseptorligander og deres anvendelse for produksjon av medikamenter
ATE486076T1 (de) 6-carboxy-normorphinan-derivate, ihre synthese und verwendung
DE602006012450D1 (de) Exo- und diastereoselektive synthese von himbacin-analoga
ITMI20040077A1 (it) Procedimento per la idrodealchilazione catalitica di idrocarburi alchilaromatici
EP1943338A4 (de) Zellfreie synthese membrangebundener polypeptide
DE602006020061D1 (de) Mucin-glycoprotein und anwendung davon
DE602006021628D1 (de) Verbesserte synthese und zubereitungen von duloxetinsalzen
DE602004009091D1 (de) Kalibration von Peak-Pattern
ATE452873T1 (de) Neues verfahren zur herstellung von (7-methoxy-1- naphtyl)acetonitril und dessen anwendung in der synthese von agomelatin
ATE417818T1 (de) Katalytisches eintopfverfahren zur synthese von isocyanaten
EP1957474A4 (de) Synthese von ftsz-hemmern
ATE382603T1 (de) Neues verfahren zur herstellung von (7-methoxy-3, 4-dihydro-1-naphtalenyl) acetonitril und dessen anwendung in der synthese von agomelatin
DE602005004685D1 (de) Tonwellenform Synthesizer
EP1943200A4 (de) Parylenvarianten und syntheseverfahren und anwendung
ATE500249T1 (de) Synthese von himbacinanaloga
ATE440856T1 (de) Festphasengebundenes thymosin-alpha1 und dessen synthese
DE602005024305D1 (de) Verfahren zu synthese von glycolonitril
IL187688A0 (en) Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators and related methods of synthesis
DE602005005645D1 (de) Stereoselektive synthese von vitamin-d-analoga
ATE395326T1 (de) Verfahren zur herstellung von (7-methoxy-1- naphthyl) acetonitril und dessen anwendung in der synthese von agomelatin